Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

Rhea-AI Summary

Neurocrine Biosciences (NBIX) has announced its participation in the Stifel 2025 Virtual CNS Forum scheduled for Tuesday, March 18, 2025, at 1:30 p.m. Eastern Time. CEO Kyle Gano and CMO Eiry Roberts will lead the presentation, which will be accessible via webcast on the company's investor relations website.

Neurocrine Biosciences is a prominent neuroscience-focused biopharmaceutical company specializing in treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company's portfolio includes FDA-approved treatments for multiple conditions including tardive dyskinesia, Huntington's disease-associated chorea, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids. Their pipeline features several compounds in mid to late-phase clinical development.

News Market Reaction

+1.73%

1 alert

+1.73% News Effect

On the day this news was published, NBIX gained 1.73%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief Medical Officer Eiry Roberts will present at the conference.

The live webcast can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes U.S. FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. 
(*in collaboration with AbbVie)

The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-stifel-2025-virtual-cns-forum-302398983.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When is Neurocrine Biosciences (NBIX) presenting at the Stifel 2025 Virtual CNS Forum?

NBIX is presenting on Tuesday, March 18, 2025, at 1:30 p.m. Eastern Time.

Who will be presenting for NBIX at the Stifel 2025 Virtual CNS Forum?

CEO Kyle Gano and Chief Medical Officer Eiry Roberts will be presenting at the forum.

What FDA-approved treatments are currently in NBIX's portfolio?

NBIX has FDA-approved treatments for tardive dyskinesia, Huntington's disease chorea, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids.

How can investors access NBIX's presentation at the Stifel CNS Forum?

Investors can access the live webcast through Neurocrine Biosciences' website under the Investors section at www.neurocrine.com.

How long will the NBIX presentation webcast replay be available?

The webcast replay will be available approximately one hour after the event and will be archived for approximately one month.